Protein Summary
Enzyme with a broad specificity. Dephosphorylates CDK2 and CDK6 in vitro. Dephosphorylates PRKAA1 and PRKAA2. Inhibits TBK1-mediated antiviral signaling by dephosphorylating it at 'Ser-172'. Plays an important role in the termination of TNF-alpha-mediated NF-kappa-B activation through dephosphorylating and inactivating IKBKB/IKKB. The protein encoded by this gene is a member of the PP2C family of Ser/Thr protein phosphatases. PP2C family members are known to be negative regulators of cell stress response pathways. This phosphatase has been shown to dephosphorylate cyclin-dependent kinases (CDKs), and thus may be involved in cell cycle control. Overexpression of this phosphatase is reported to cause cell-growth arrest or cell death. Alternative splicing results in multiple transcript variants encoding different isoforms. Additional transcript variants have been described, but currently do not represent full-length sequences. [provided by RefSeq, Jul 2008]
- ENST00000282412
- ENSP00000282412
- ENSG00000138032
- ENST00000345249
- ENSP00000326089
- ENST00000378551
- ENSP00000367813
- ENST00000409432
- ENSP00000387287
- PP2CB
- PP2CB
- PP2CBETA
- PP2C-beta
- PPC2BETAX
- PP2C-beta-X
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
transcription factor perturbation | 0.98 | ||
virus perturbation | 0.98 | ||
kinase perturbation | 0.95 | ||
interacting protein | 0.93 | ||
disease perturbation | 0.87 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 48.09 (req: < 5)
Gene RIFs: 21 (req: <= 3)
Antibodies: 315 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 48.09 (req: >= 5)
Gene RIFs: 21 (req: > 3)
Antibodies: 315 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 10
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 5
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0